|
Parameter
|
Placebo (n = 20)
|
ASC (n = 40)
|
P-value
|
|---|
|
Age (years)
|
65.3 ± 8.7
|
65.5 ± 9.7
|
0.94
|
|
Male gender
|
20 (100)
|
35 (87.5)
|
0.02
|
|
BMI (kg/m2)
|
30.0 ± 4.8
|
30.0 ± 4.1
|
0.92
|
|
Smoking
|
0.19
|
|
Current
|
3 (15)
|
8 (20)
| |
|
Previous
|
16 (80)
|
23 (57.5)
| |
|
Never
|
1 (5)
|
9 (22.5)
| |
|
Diabetes mellitus
|
6 (30)
|
16 (40)
|
0.57
|
|
Hypertension
|
12 (60)
|
33 (82.5)
|
0.06
|
|
Previous AMI
|
10 (50)
|
26 (65)
|
0.26
|
|
Previous CABG
|
20 (100)
|
33 (82.5)
|
0.08
|
|
Previous PCI
|
15 (75)
|
28 (70)
|
0.69
|
|
LVEF (%)
|
54 ± 8
|
52 ± 8
|
0.38
|
- AMI acute myocardial infarction, ASC adipose-derived stromal cell, BMI body mass index, CABG coronary artery bypass grafting, LVEF left ventricular ejection fraction, n number of patients, PCI percutaneous coronary intervention
